N 1 (186) 2024 р. P. 88–94

MARKETING RESEARCH OF THE PHARMACEUTICAL MARKET OF UKRAINE IN THE SEGMENT OF ANTIVIRAL DRUGS FOR SYSTEMIC USE

N. A. Kopak, S. V. Vasyliuk

Lviv Polytechnic National University, Lviv, Ukraine

The present paper provides an overview of the domestic pharmaceutical market, in particular, of the J05 ATC group – antiviral drugs for systemic use.

Objective – conducting marketing research of the pharmaceutical market of Ukraine in the segment of antiviral drugs for systemic use: structuring data on their assortment, the ratio of imported to domestic drugs, the availability of the assortment, comparison of retail prices, and determination of social and economic affordability.

Materials and methods: data from the State Register of Medicines of Ukraine. Analytical techniques involved logical, mathematical, statistical, methodical, and comparative methods.

The analysis of Ukraine’s domestic market for antiviral drugs, using the State Register of Medicines, brings forth significant insights. The dataset comprises 277 registered medicines within this category. Acyclovir stands out as the most prevalent. Beyond the domestic landscape, the study delves into the global presence of antiviral drugs, uncovering representation from 18 different countries. Indian-produced drugs dominate this scenario, comprising 44.2% of the total while Ukrainian-produced drugs constitute 19.9%. The study extends its focus to the socioeconomic accessibility within the Ukrainian pharmaceutical market. Noteworthy findings state that drugs from Ukrainian manufacturers are among the most readily available and economically accessible.

Conclusion. The conducted study encourages consideration of local drug development initiatives to enhance the affordability and accessibility of antiviral medications for the Ukrainian population.

Key words: antiviral drugs, pharmaceutical market, socio-economic accessibility, State Register of Medicines.

REFERENCES

  1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020; 55(3). doi: https://doi.org/10.1016/j.ijantimicag.2020.105924.
  2. Public health center of the Ministry of Health of Ukraine. Available from: https://npsi.phc.org.ua/MortalityDashboard.
  3. Cascini F, Hoxhaj I, Zaçe D, Ferranti M, Di Pietro ML, Boccia S, Ricciardi W. How health systems approached respiratory viral pandemics over time: a systematic review. BMJ Global Health. 2020; 5(12). doi: https://doi.org/10.1136/bmjgh-2020-003677.
  4. Safdar A, Hasan R, Riaz H. Antiviral drugs and their targets. Frontiers in pharmacology. 2015; 6, 181. doi: https://doi. org/10.3389/fphar.2015.00181.
  5. CDC (2019). Viral Hepatitis. Centers for Disease Control and Prevention. Available from: https://www.cdc.gov/hepatitis/htm.
  6. Dietmar A, Angelika M, Adolf E. Relationship between depression, anxiety, stress, and SARS-CoV-2 infection: a longitudinal study. Frontiers in Psychology. 2023; 14. doi: https://doi.org/10.3389/fpsyg.2023.1116566.
  7. Coughlin S. Anxiety and Depression: Linkages with Viral Diseases. Public Health Reviews.2012; 34(7). doi: https://doi. org/10.1007%2FBF03391675.
  8. Mitrica B, Mocanu I, Grigorescu I, et al. Population Vulnerability to the SARS-CoV-2 Virus Infection. A County-Level Geographical-MethodologicalApproach in Romania. 2021; 5(11). doi: https://doi.org/10.1029/2021GH000461.
  9. Foster MA, Hofmeister MG, Kupronis BA et al. Increase in Hepatitis A Virus Infections – United States, 2013–2018. MMWR Morb Mortal Wkly Rep. 2019; 68(18). doi: https://doi.org/10.15585%2Fmmwr.mm6818a2.
  10. An overview of the pharmaceutical market of Ukraine in times of difficult trials. Available from: https://promoboz.com/ journal/2023/1-94-2023/oglyad-farmatsevtychnogo-rynku-ukrayiny-v-chasy-vazhkyh-vyprobuvan/.
  11. State register of medicines. Available from: http://www.drlz.com.ua (Last accessed: March 2023).
  12. Popova IA, Kurylenko YE, Podgayna MV, Podkolzina MV. Evaluation of competitive advantages of pharmacy chains in Ukraine. Modern Economics. 2022; 31, 104–112. doi: https://doi.org/10.31521/modecon.V31(2022)-15.
  13. Official site of Tabletki UA. Available from: https://tabletki.ua/.
  14. Who owns the largest pharmacy chains in Ukraine. Available from: https://rau.ua/novyni/volodari-aptek/.
  15. Olkhovska A, Stremoukhov O, Spiridonov S, Hrybnyk I, Kutsenko S. Justification of the expediency of creating new medicines and ginkgo dietary supplements biloba based on a study of the pharmaceutical market of Ukraine. Modern medicine, pharmacy and psychological health. 2022; 2 (9). doi: https://doi.org/10.32689/2663-0672-2022-2-10.
  16. Symonenko NA, Podgayna MV, Nemchenko AS, Shpychak OS. Analysis economic availability of certain groups of cardiac drugs in Ukraine from 2016 to 2020 years. Pharmaceutical journal. 2021; 2: 79–86. doi: https://doi.org/10.11603/2312-0967.2021.2.12183.
View article PDF